8-K: Intelligent Bio Solutions Reports Fiscal Q2 2025 Financial Results, Highlights 32.6% Gross Profit Increase

Intelligent Bio Solutions Inc. announced its fiscal Q2 2025 financial results, showcasing a 32.6% increase in gross profit and progress towards entering the U.S. market.

Summary

• Intelligent Bio Solutions Inc. (INBS) announced its financial results for the second fiscal quarter and six months ended December 31, 2024.
• The company reported a 32.6% increase in gross profit for the six months ended December 31, 2024.
• Gross profit margin increased to 38.5% from 27.7% for the same period year-over-year.
• The company submitted its FDA 510(k) pre-market notification in December and remains on track for U.S. market expansion in 2025.
• INBS secured 19 new accounts during the quarter, bringing the total to over 400 active customer accounts in 19 countries.
• Total cash and cash equivalents as of December 31, 2024, were $2.24 million.
• Shareholders' equity as of December 31, 2024, was $4.20 million.
• Total revenues for the fiscal second quarter were $0.61 million.
• Total revenue for the six months ended December 31, 2024, was $1.48 million.
• Net loss for the fiscal second quarter was $2.26 million, including $0.32 million in non-cash expenses.
• The company expects cartridge sales to continue outpacing reader sales.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the increase in gross profit and progress with FDA submission, but tempered by the net loss and decrease in revenue from sales of goods.

Positives

• The company achieved a 32.6% increase in gross profit for the six months ended December 31, 2024.
• Gross profit margin improved significantly, reaching 38.5%.
• The FDA 510(k) submission marks a significant regulatory milestone.
• Strategic partnerships are expanding the company's reach in the Asia-Pacific region and the U.S.
• The customer base continues to grow, with over 400 active accounts.
• The company is focusing on higher-margin cartridge sales to drive revenue.

Negatives

• Revenue from sales of goods decreased for both the three and six months ended December 31, 2024, compared to the same periods in 2023.
• The net loss attributable to the company increased for both the three and six months ended December 31, 2024, compared to the same periods in 2023.
• The net loss for the fiscal second quarter was $2.26 million.

Risks

• The company's ability to successfully navigate the FDA approval process is crucial for its U.S. market entry.
• Continued investment in R&D and expansion efforts may impact profitability in the short term.
• The company faces competition in the drug screening market.
• The company's future success depends on its ability to scale its customer base and expand its international presence.

Future Outlook

The company expects cartridge sales to continue outpacing reader sales and anticipates growth as it enters the U.S. market in 2025.

Management Comments

• Harry Simeonidis, President and CEO, stated that the business model is excelling with higher-margin cartridge sales contributing to gross profit and margin growth.
• Spiro Sakiris, CFO, noted that the company has made strides in sustaining long-term financial strength.

Industry Context

The company operates in the medical technology sector, specifically focusing on drug screening solutions. The submission of the FDA 510(k) application is a critical step towards entering the large U.S. market, where it will compete with established players in the point-of-care testing and drug screening industries.

Comparison to Industry Standards

• It's difficult to provide a direct comparison without knowing the specific revenue and profitability metrics of direct competitors in the fingerprint drug screening market.
• Companies like Abbott, Roche, and Siemens Healthcare are major players in the broader diagnostics market, but they don't directly compete with INBS's fingerprint sweat analysis technology.
• Compared to traditional drug testing methods (urine, blood, saliva), INBS's technology offers a non-invasive and rapid alternative, potentially giving it a competitive edge in certain segments.

Stakeholder Impact

• Shareholders may be encouraged by the increase in gross profit and progress towards U.S. market entry.
• Employees may benefit from the company's expansion and growth.
• Customers will have access to a new drug screening technology.
• Suppliers may see increased demand for cartridges and other related products.

Next Steps

• The company will continue to pursue FDA clearance for its Intelligent Fingerprinting Drug Screening System.
• The company plans to expand into the U.S. market in 2025.
• The company will focus on growing cartridge sales and expanding its customer base.

Key Dates